An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease.
BACKGROUND
The lack of a complete understanding of the complex processes involved in the etiopathogenesis and subsequent appropriate phenotyping makes it difficult to find therapies that may be efficacious in most patients with osteoarthritis (OA). Consensus recommendations involve mainly non-pharmacological approaches. Analgesics and NSAIDs are considered second choice options due to their poor efficacy/safety ratios. To some extent, OA may be considered an orphan disease. Therefore, there is an urgent need to identify effective and safe new pharmacologic modalities for treating OA.


METHODS
This review is based on a Medline comprehensive literature search for published articles evaluating new formulations of current drugs and promising emerging therapies in OA. We discuss the current status of novel systemic agents in development including potent analgesic options, inhibitors of innate immunity, inducible nitric oxide synthase (iNOS), pro-inflammatory cytokines and cartilage proteases as well as bone agents. Furthermore, we also revise the potential benefit of intraarticular (IA) therapy with hyaluronic acid (HA), pro-inflammatory mediator blockers, cartilage anabolic agents, mesenchymal stem cell and gene transfer.


CONCLUSIONS
Despite the renewed interest in the search of new compounds for treatment of OA, results have been limited. Novel systemic and IA administered agents are in active development. IA drug administration is particularly an attractive approach because can diminish some of the severe side effects associated with systemic drugs. Indeed, one of the most promising fields for pharmacology innovation in OA is joint injected therapy, as suggested by preliminary data from recent studies using IA sprifermin (rhFGF-18), mesenchymal stem cells or TGF-B1 transduced allogenic chondrocytes. Last, the effort to develop new drugs must be accompanied by the interest for establishing well-defined phenotypes, and only then, a more tailored therapy should be practiced in OA.
a Bone and Joint Research Unit, Service of Rheumatology, IIS-Fundación Jiménez Díaz , Autonomous University of Madrid , Madrid , Spain.
Jorge A
JA
Roman-Blas
b UOS of Rheumatology , S. Pietro Fatebenefratelli Hospital , Rome , Italy.
Emanuele
E
Bizzi
a Bone and Joint Research Unit, Service of Rheumatology, IIS-Fundación Jiménez Díaz , Autonomous University of Madrid , Madrid , Spain.
Raquel
R
Largo
b UOS of Rheumatology , S. Pietro Fatebenefratelli Hospital , Rome , Italy.
Alberto
A
Migliore
a Bone and Joint Research Unit, Service of Rheumatology, IIS-Fundación Jiménez Díaz , Autonomous University of Madrid , Madrid , Spain.
Gabriel
G
Herrero-Beaumont
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002356:Cartilage / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D006820:Hyaluronic Acid
DMOADs; Osteoarthritis; SYSADOAs; intraarticular therapy; therapy